Aptorum Soars 234.65% on $1.28B Surge, Ranks 44th in Market Activity as DiamiR's Alzheimer's Test Gains NYSDOH Approval

On August 21, 2025, Aptorum Group (NASDAQ: APM) surged 234.65% with a trading volume of $1.28 billion, ranking 44th in market activity. This follows DiamiR Biosciences' receipt of New York State Department of Health (NYSDOH) approval for its APOE Genotyping test, a key diagnostic tool for Alzheimer’s risk assessment. The approval enables DiamiR to offer the test across multiple biological samples, expanding its market reach through a CLIA-certified, CAP-accredited lab. This development strengthens Aptorum’s diagnostic portfolio, particularly in neurodegenerative diseases, aligning with its merger strategy to integrate DiamiR’s capabilities by Q4 2025.

The NYSDOH’s Clinical Laboratory Evaluation Program (CLEP) is renowned for rigorous validation standards, underscoring the credibility of DiamiR’s test. The APOE ε4 allele is a critical genetic risk factor for late-onset Alzheimer’s, with carriers facing significantly elevated risks. By broadening access to this test, Aptorum positions itself to capitalize on growing demand for biomarker-driven diagnostics in neurology. The test’s versatility across sample types enhances clinical utility, supporting personalized care strategies and trial enrollment—a timely advantage as novel Alzheimer’s therapies gain traction.

The merger between Aptorum and DiamiR, finalized in July 2025, aims to consolidate diagnostic and therapeutic assets under one entity. This strategic alignment reflects Aptorum’s focus on unmet medical needs in oncology and neurology. While regulatory and shareholder approvals remain pending, the NYSDOH approval signals progress toward operational integration. The transaction is expected to close by year-end, potentially amplifying Aptorum’s market presence in the $10 billion diagnostics sector.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a CAGR of 6.98% and a maximum drawdown of 15.59%. Despite steady growth, a significant downturn in mid-2023 highlights the necessity of risk management in volume-driven strategies.